Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report

Giacomo Barchiesi, Eriseld Krasniqi, Maddalena Barba, Marina Della Giulia, Laura Pizzuti, Gioia Massimiani, Gennaro Ciliberto, Patrizia Vici

Research output: Contribution to journalArticlepeer-review

Abstract

In estrogen receptor-positive HER2-negative (ER+HER2-) metastatic breast cancer, chemotherapy should be offered only to patients who develop endocrine resistance or have a rapid disease progression. However, the correct sequence of chemotherapy administration is still debated.Patient concerns:We report the case of a 49-year-old woman with ER+ HER2- metastatic breast cancer who experienced an exceptionally long response to capecitabine administered as second-line therapy following a first-line anthracycline-based chemotherapy.Diagnoses:The patient was diagnosed with ER+ HER2- metastatic breast cancer with massive liver involvement and mediastinal lymph nodes metastasis.Interventions:This patient was treated with capecitabine 1000mg/mq bid given intermittently for 14 days within a 21-day cycle as a second-line therapy following a rapid progression on letrozole treatment given as a maintenance therapy.Outcomes:Our patient experienced a progression-free survival (PFS) >3 years with an exceptionally good quality of life (QoL).Lessons:In ER+HER2- metastatic breast cancer patients, capecitabine monochemotherapy in second line may be associated with a particularly satisfactory PFS and no impact in terms of QoL. Future studies focused on biomarkers with predictive ability may help select patients who represent the best candidates to this treatment.

Original languageEnglish
Article numbere17135
JournalMedicine (United States)
Volume98
Issue number37
DOIs
Publication statusPublished - Sep 1 2019

Keywords

  • capecitabine
  • chemotherapy
  • long response
  • metastatic breast cancer

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report'. Together they form a unique fingerprint.

Cite this